For peripheral artery disease, which therapeutic measures are commonly used?

For peripheral artery disease, which therapeutic measures are commonly used?

• A. Compression stockings, Cilostazol, Pentoxifylline
• B. Oral anticoagulants alone
• C. Immediate bypass surgery
• D. Bed rest and elevation

Answer: (A)

In PAD, the goal is to relieve claudication and improve walking distance while also addressing cardiovascular risk. Cilostazol is a phosphodiesterase-3 inhibitor that increases cAMP in vascular smooth muscle and platelets, producing vasodilation and improved symptoms of intermittent claudication. Because of that, it’s a common prescription for patients who have stable claudication and no heart failure or significant bradyarrhythmia. Pentoxifylline works by reducing blood viscosity and improving red blood cell deformability, which can help microcirculation. The evidence for meaningful, consistent improvement in claudication is more modest, but it remains a commonly encountered option as an adjunct when other therapies are not suitable or well tolerated. Compression stockings serve as an adjunct for leg edema and venous insufficiency. In PAD, they aren’t a primary treatment to improve arterial blood flow, but they can improve leg comfort and edema control, and may aid wound healing in cases with ulcers when used carefully and appropriately. They must be used with caution because excessive compression can worsen perfusion in diseased limbs. Together, these measures illustrate how PAD management combines symptom-directed therapies (cilostazol, sometimes pentoxifylline) with adjuncts for edema and comfort (compression stockings) alongside vascular risk modification.

In PAD, the goal is to relieve claudication and improve walking distance while also addressing cardiovascular risk. Cilostazol is a phosphodiesterase-3 inhibitor that increases cAMP in vascular smooth muscle and platelets, producing vasodilation and improved symptoms of intermittent claudication. Because of that, it’s a common prescription for patients who have stable claudication and no heart failure or significant bradyarrhythmia.

Pentoxifylline works by reducing blood viscosity and improving red blood cell deformability, which can help microcirculation. The evidence for meaningful, consistent improvement in claudication is more modest, but it remains a commonly encountered option as an adjunct when other therapies are not suitable or well tolerated.

Compression stockings serve as an adjunct for leg edema and venous insufficiency. In PAD, they aren’t a primary treatment to improve arterial blood flow, but they can improve leg comfort and edema control, and may aid wound healing in cases with ulcers when used carefully and appropriately. They must be used with caution because excessive compression can worsen perfusion in diseased limbs.

Together, these measures illustrate how PAD management combines symptom-directed therapies (cilostazol, sometimes pentoxifylline) with adjuncts for edema and comfort (compression stockings) alongside vascular risk modification.